Peripheral Arterial Disease (PAD) is an atherosclerotic condition that is caused by reduced blood flow to the legs which can provoke symptoms of leg pain (“intermittent claudication”) during exercise. PAD is the most common initial cardiovascular manifestation in T2D patients, and patients with PAD are at high risk for myocardial infarction, stroke, and all-cause mortality. Globally, >200 million people were living with PAD 2010, an almost 24% increase in 10 years. PAD is under-diagnosed and under-treated, there are limited therapeutic options. Thus, PAD represents a large clinical need.
O304 and PAD
O304 increases microvascular perfusion in animals, and as assessed by MRI in calf muscle of T2D patients and in non-diabetic obese subjects, some of which with reduced perfusion resembling PAD patients. These results raise the possibility that O304 may be developed as treatment for Fontaine class II (claudicants) and class III (rest pain) PAD patients, without critical ischemia but with occlusions that are too long to warrant simple vascular surgery.